Remove Big Data Remove Development Remove Doctors Remove Genomics
article thumbnail

Digitalising drug discovery

pharmaphorum

The oceans of health data out there can be overwhelming for pharma companies to manage – but if extracted correctly, the prospect to develop drugs from scratch in as little as a year is very real, says Lifebit CEO, Dr Maria Chatzou Dunford. . on Big data: astronomical or genomical? ,

article thumbnail

Medical Informatics: a bridge between two worlds

pharmaphorum

Dennis Kadioglu is the deputy head of both the Medical Informatics Group (MIG) and the Data Integration Center (DIC) at the University Hospital Frankfurt in Frankfurt am Main. In 2021, she co-founded OHDSI Germany, which is as a national node of the Observational Health Data Sciences and Informatics (OHDSI) Europe. .

Genome 58
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Medical Informatics and Rare Disease: a bridge between two worlds

pharmaphorum

And this is where modern technologies and data-driven medical informatics can really bridge the gaps in rare disease research,” said Dr Joanne Hackett, head of Genomic and Precision Medicine at IQVIA, during a recent pharmaphorum webinar. Data privacy and protection, patient voice.

Genome 105
article thumbnail

Healthcare in 2021: Top Disruptions Bound To Impact The Way Healthcare Is Delivered

Delveinsight

Almost all the aspects of the healthcare sector, such as service delivery, communications, operation, medical equipment, and drug development, have grown remarkably and improved the overall health outcome. Improvement in the diagnostics, management of chronic conditions, drug and device development, are some of the key applications of AI.

Doctors 52
article thumbnail

Kiromic Announces the Filing of Key European Patents for Its Chimeric PD-1 (chPD1) Target

The Pharma Data

Kiromic’s deep understanding of the tumor micro environment (TME) and the tumors’ escape and masking mechanisms led to development of a promising platform for chimeric antigen receptor therapy (CAR-T). PD-1 has always been a challenge for CAR-T development. “We believe Prof. About PD-1 Check-point inhibition.

In-Vivo 40
article thumbnail

The rise of real-world evidence: unlocking the potential in EHRs

pharmaphorum

By extracting and reading unstructured information buried within the free text of clinical notes, Savana’s technology and clinical research methodology is enabling clinicians and health researchers around the world to analyse vast amounts of previously inaccessible clinical data. “We Fragmentation of information is our enemy. About Savana.

Doctors 113